Cargando…

Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring

Deferasirox (DFX) is the newest among three different chelators available to treat iron overload in iron-loading anaemias, firstly released as Dispersible Tablets (DT) and more recently replaced by Film-Coated Tablets (FCT). In this retrospective observational study, pharmacokinetics, pharmacodynami...

Descripción completa

Detalles Bibliográficos
Autores principales:	Piolatto, Andrea, Berchialla, Paola, Allegra, Sarah, De Francia, Silvia, Ferrero, Giovanni Battista, Piga, Antonio, Longo, Filomena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206201/ https://www.ncbi.nlm.nih.gov/pubmed/34131221 http://dx.doi.org/10.1038/s41598-021-91983-w

Ejemplares similares

Ineffective Erythropoiesis in β-Thalassaemia: Key Steps and Therapeutic Options by Drugs
por: Longo, Filomena, et al.
Publicado: (2021)

The Influence of Cardiovascular Risk Factors and Hypogonadism on Cardiac Outcomes in an Aging Population of Beta-Thalassemia Patients
por: Barbero, Umberto, et al.
Publicado: (2021)

Evaluation of Sex Differences in Preclinical Pharmacology Research: How Far Is Left to Go?
por: Allegra, Sarah, et al.
Publicado: (2023)

Evaluation of Pharmacokinetics and Pharmacodynamics of Deferasirox in Pediatric Patients
por: Galeotti, Laura, et al.
Publicado: (2021)

Hypersensitivity reaction with deferasirox
por: Sharma, Atul, et al.
Publicado: (2015)

Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions
por: Chalmers, Anna W, et al.
Publicado: (2016)

Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity()
por: Spini, Andrea, et al.
Publicado: (2021)

Does Hepcidin Tuning Have a Role among Emerging Treatments for Thalassemia?
por: Longo, Filomena, et al.
Publicado: (2022)

Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload
por: Taher, Ali, et al.
Publicado: (2009)

PB2506: EVIDENCE OF SPLEEN STIFFNESS PROGRESSION BY TRANSIENT ELASTOGRAPHY IN SCD PATIENTS: RESULTS FROM AN EXPLORATORY STUDY
por: Piolatto, Andrea, et al.
Publicado: (2023)

New film‐coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower‐risk MDS: Results of the randomized, phase II ECLIPSE study
por: Taher, Ali T., et al.
Publicado: (2017)

Deferasirox: Duodenal perforation: case report
Publicado: (2021)

Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
por: Wu, Dijiong, et al.
Publicado: (2018)

Exercise Stress Echocardiography with Tissue Doppler Imaging (TDI) Detects Early Systolic Dysfunction in Beta-Thalassemia Major Patients without Cardiac Iron Overload
por: Barbero, Umberto, et al.
Publicado: (2012)

Colorectal cancer chemotherapy: can sex-specific disparities impact on drug toxicities?
por: De Francia, Silvia, et al.
Publicado: (2022)

P1511: EFFICACY AND SAFETY OF COMBINATION IRON CHELATION THERAPY WITH DEFERIPRONE AND DEFERASIROX IN PATIENTS WITH Β-THALASSEMIA MAJOR: A SYSTEMATIC LITERATURE REVIEW
por: Piga, A., et al.
Publicado: (2022)

Update on the use of deferasirox in the management of iron overload
por: Taher, Ali, et al.
Publicado: (2009)

Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent
por: Lee, Ji Won, et al.
Publicado: (2013)

Deferasirox: Over a Decade of Experience in Thalassemia
por: Moukalled, Nour M., et al.
Publicado: (2018)

Deferasirox – a rarer cause of Fanconi syndrome
por: Khan, Iman, et al.
Publicado: (2019)

Synthesis and Study of Multifunctional Cyclodextrin–Deferasirox Hybrids
por: Gascon, Jose Miguel, et al.
Publicado: (2019)

Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study
por: Tartaglione, Immacolata, et al.
Publicado: (2020)

Treating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence
por: Longo, Filomena, et al.
Publicado: (2023)

Cost-utility of new film-coated tablet formulation of deferasirox vs deferoxamine among major beta-thalassemia patients in Iran
por: Saiyarsarai, Parisa, et al.
Publicado: (2020)

Transfusion-dependent low-risk myelodysplastic patients receiving deferasirox: Long-term follow-up
por: IMPROTA, SALVATORE, et al.
Publicado: (2013)

Deferasirox Reduces Oxidative Stress in Patients With Transfusion Dependency
por: Saigo, Katsuyasu, et al.
Publicado: (2013)

Deferasirox: appraisal of safety and efficacy in long-term therapy
por: Chaudhary, Preeti, et al.
Publicado: (2013)

Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients
por: Votavova, Hana, et al.
Publicado: (2021)

Effects of Deferasirox in Alzheimer’s Disease and Tauopathy Animal Models
por: Kwan, Ping, et al.
Publicado: (2022)

Deferasirox Nanosuspension Loaded Dissolving Microneedles for Intradermal Delivery
por: Faizi, Hafsa Shahid, et al.
Publicado: (2022)

Iron Chelation Therapy with Deferasirox in the Management of Iron Overload in Primary Myelofibrosis
por: Elli, Elena Maria, et al.
Publicado: (2014)

Renal Function in Patients with Thalassemia Major Receiving Exjade(®) Dispersible Tablets and a New Film-coated Tablet Formulation of Deferasirox (Nanojade(®))
por: Falahati, Vahid, et al.
Publicado: (2022)

Patient preference for deferasirox film-coated versus dispersible tablet formulation: a sequential-design phase 2 study in patients with thalassemia
por: Viprakasit, Vip, et al.
Publicado: (2023)

COVID-19 Prevention and Treatment
por: De Francia, Silvia, et al.
Publicado: (2023)

Deferasirox in Indian children with thalassemia major: 3 years experience
por: Dhamija, Mayank, et al.
Publicado: (2013)

The potential of deferasirox as a novel therapeutic modality in gastric cancer
por: Choi, Jung Hye, et al.
Publicado: (2016)

Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma
por: Saeki, Issei, et al.
Publicado: (2016)

Perforated duodenal ulcer: A rare complication of deferasirox in children
por: Yadav, Sunil Kumar, et al.
Publicado: (2013)

Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome
por: Polat, Asude Kara, et al.
Publicado: (2017)

Protein Carbonylation in Patients with Myelodysplastic Syndrome: An Opportunity for Deferasirox Therapy
por: Rodríguez-García, Alba, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vk1ni161c765046i0ano05lb6a